


**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) An isolated, purified or synthetic compound selected from the group consisting of pomolic acid, its-isomers of pomolic acid and derivatives thereof, wherein the compound is effective to treatcharacterized by their use in the treatment of multidrug resistant tumours., with the structure (I):

(I)



2. (Currently Amended) A pharmaceutical composition for the treatment oftreating multidrug resistant tumourtumors, said composition comprising an effective amount of at least one compound ofcharacterized by the fact of containing a sufficient amount of pomolic acid, its isomers or derivatives in accordance with claim 1 and at least one pharmaceutically acceptable vehiclepharmaceutical accepted vehicles.

3. (Currently Amended) The pharmaceutical composition, in accordance with claim 2, characterized by the fact thatwherein the at least one pharmaceutically acceptable vehicle should beis acceptable for systemic or oral administration.

4. (Currently Amended) The pharmaceutical composition; in accordance with claim 2, characterized by the fact thatwherein the at least one pharmaceutically acceptable vehicle is an organic solvent, further diluted in a saline solution or another equivalent isotonic solution.

5. (Currently Amended) The pharmaceutical composition; in accordance with claim 4, characterized by the fact ofwherein the organic solvent be-is dimethylsulfoxide or another organic solvent acceptable to be used in humans, diluted in a saline solution.

6. (Currently Amended) The pharmaceutical composition; in accordance with claim 2, characterized by thewherein a concentration of the compound pomolic acid, its isomers and/or derivatives, being utilized between is from 0.1% and to 100% in weight/volume.

7. (Currently Amended) The pharmaceutical composition; in accordance with claim 6, characterized by the fact thatwherein the concentration of pomolic acid, its isomers and/or derivatives, being utilized is 10mg/ml to 1000 mg/ml.

8. (Currently Amended) A method to prepare the pharmaceutical composition for the treatment of treating multidrug resistant tumors, said method comprising solubilizing at least one compound selected from the group consisting of characterized by having a first step for the solubilization of pomolic acid, its isomers of pomolic acid and/or derivatives thereof, in dimethylsulfoxide or another pharmaceutically acceptable solvent for human use, followed by dilution in saline solution, in such a way that the a concentration of dimethylsulfoxide the pharmaceutically acceptable solvent does not exceed 1%.

9. (Currently Amended) The method to prepare the pharmaceutical composition; in accordance with claim 8, characterized by the fact that thewherein a concentration of the at least one compound is pomolic acid, its isomers and/or derivatives utilized in the first step of solubilization being 10mg/ml to 1000 mg/ml.

10. (Currently Amended) A mMethod for the treatment of multidrug resistance tumourtumors characterized by thecomprising administration of a therapeutically efficacious amount of at least one compound selected from the group consisting of pomolic acid, its isomers of pomolic acid and/or derivatives thereof.

11. (Currently Amended) The mMethod for treatment, in accordance with claim 10, characterized bywherein the administration of a therapeutically efficacious amount of pomolic acid, its isomers and/or derivatives is systemic or oral.

12. (Currently Amended) The mMethod for treatment, in accordance with claim 11, characterized bywherein the therapeutically efficacious amount of pomolic acid, its isomers and/or derivatives, being betweenis from 0.01mg/kg and to 100mg/kg body weight.

13. (Canceled).

14. (Canceled).